Decreasing prevalence of isolates with vancomycin heteroresistance and vancomycin minimum inhibitory concentrations ≥2mg/L in methicillin-resistant Staphylococcus aureus over 11years: Potential impact of vancomycin treatment guidelines

Diagnostic Microbiology and Infectious Disease

Volumn 82, Issue 3, 2015, Pages 245-248

  Khatib, Riad ^a   Sharma, Mamta ^a   Johnson, Leonard B ^a   Riederer, Kathleen ^a   Shemes, Stephen ^a   Szpunar, Susan ^a  

^a ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Bacteremia; Heteroresistance; Staphylococcus aureus; Vancomycin

Indexed keywords

VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MOLECULAR TYPING; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTOCOL COMPLIANCE; RETROSPECTIVE STUDY; SCCMEC TYPING; TREND STUDY; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; ADOLESCENT; BACTEREMIA; DRUG EFFECTS; DRUG TOLERANCE; DRUG UTILIZATION; FEMALE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; STANDARDS; STAPHYLOCOCCAL INFECTIONS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG TOLERANCE; DRUG UTILIZATION; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN; YOUNG ADULT;

EID: 84941878483     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2015.03.014     Document Type: Article

References (30)

1. Alos J.I., Garcia-Canas A., Garcia-Hierro P., Rodríguez-Salvanés F. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. J Antimicrob Chemother 2008, 62:773-775.
2. Bhalodi A.A., Hagihara M., Nicolau D.P., Kuti J.L. In vitro pharmacodynamics of human simulated exposures of ceftraoline and daptomycin against MRSA, hVISA and VISA with and without prior vancomycin exposure. Antimicrob Agents Chemother 2014, 58:672-677.
3. 24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization. J Antimicrob Chemother 2012, 56:634-638.
4. Chen S.Y., Liao C.H., Wang J.L., Chiang W.C., Lai M.S., Chie W.C., et al. Methicillin-resistant Staphylococcus aureus cassette chromosome mec genotype effects outcomes of patients with healthcare-associated MRSA bacteremia independently of vancomycin minimum inhibitory concentrations. Clin Infect Dis 2012, 55:1329-1337.
5. Chen C.-J., Lin M.-H., Shu J.-C., Lu J.-J. Reduced susceptibility to vancomycin in isogenic Staphylococcus aureus strains of sequence type 59: tracking evolution and identifying mutations by whole-genome sequencing. J Antimicrob Chemother 2014, 69:349-354.
6. Chua T., Moore C.L., Perri M.B., Donabedian S.M., Masch W., Vager D., et al. Molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates in urban Detroit. J Clin Microbiol 2008, 46:2345-2352.
7. Edwards B., Milne K., Lawes T., Cook I., Robb A., Gould I.M. Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from north east Scotland from 2006 to 2010. J Clin Microbiol 2012, 50:318-325.
8. Gasch O., Ayats J., Domingues M.A., Tubau F., Linares J., Pena C., et al. Epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection: secular trends over 19years at a university hospital. Medicine 2011, 90:319-327.
9. Han J.H., Edelstein P.H., Lautenbach E. Reduced vancomycin susceptibility and staphylococcal cassette chromosome mec (SCCmec) type and distribution in methicillin-resistant Staphylococcus aureus bacteremia. J Antimicrob Chemother 2012, 67:2346-2349.
10. Holmes R.L., Jorgensen J.H. Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against methicillin-resistant Staphylococcus isolates obtained from 1999 through 2006. Antimicrob Agents Chemother 2008, 52:757-760.
11. Jones R.N. Microbiological features if vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006, 42(S1):S13-S24.
12. Khatib R., Jose J., Johnson L.B., Riederer K., Shemes S. An optimal method for generating stable vancomycin heteroresistance and intermediate susceptibility in methicillin-resistant Staphylococcus aureus blood isolates under in-vitro vancomycin pressure. J Microbiol Infect Dis 2012, 2:129-134.
13. Khatib R., Sharma M., Iyer S., Fakih M.G., Obeid K.M., Venugopal A., et al. Decreasing incidence of Staphylococcus aureus bacteremia over 9years: greatest decline in community-associated methicillin-susceptible and hospital-acquired methicillin-resistant isolates. Am J Infect Control 2013, 41:210-213.
14. Kullar R., Rybak M.J., Kaye K.S. Comparative epidemiology of bacteremia due to methicillin-resistant Staphylococcus aureus between older and younger adults: a propensity score analysis. Infect Control Hosp Epidemiol 2013, 34:400-406.
15. Liu C., Bayer A., Cosgrove S.E., Daum R.S., Fridkin S.K., Gorwitz R.J., et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011, 52:1-38.
16. Miller C.E., Batra R., Cooper B.S., Patel A.K., Klein J., Otter J.A., et al. An association between bacterial genotype combined with a high-vancomycin minimum inhibitory concentration and risk of endocarditis in methicillin-resistant Staphylococcus aureus bloodstream infection. Clin Infect Dis 2012, 54:591-600.
17. Moore C.L., Osaki-Kiyan P., Haque N.Z., Perri M.B., Donabedian S., Zervos M.J. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 2012, 54:51-58.
18. Musta A.C., Riederer K., Shemes S., Chase P., Jose J., Johnson L.B., et al. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11years. J Clin Microbiol 2009, 47:1640-1644.
19. Pitz A.M., Yu F., Hermsen E.D., Rupp M.E., Fey P.D., Olsen K.M. Vancomycin susceptibility trends and prevalence of vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates. J Clin Microbiol 2011, 49:269-274.
20. Richter S.S., Diekema D.J., Heilmann K.P., Dohrn C.L., Crispell E.K., Riahi F., et al. Activity of vancomycin, ceftraoline, and mupricin against Staphylococcus aureus isolates collected in a 2011 national surveillance study in the United States. Antimicrob Agents Chemother 2014, 58:740-745.
21. Riederer K., Shemes S., Chase P., Musta A., Mar A., Khatib R. Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and agar screening methods. J Clin Microbiol 2011, 49:214-550.
22. Rossi F., Diaz L., Wollam A., Panesso D., Zhou Y., Rincon S., et al. Transferable vancomycin resistance in a community-associated MRSA lineage. N Engl J Med 2014, 370:1524-1531.
23. Sader H.S., Fey P.D., Fish D.N., et al. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother 2009, 53:4127-4132.
24. Sancak B. What is the reason for conflicting results for vancomycin minimum inhibitory concentration values for methicillin-resistant Staphylococcus aureus. Scand J Infect Dis 2014, 46:158-160.
25. Sancak B., Yagci S., Gur D., Gulay Z., Ogunc D., Soyletir G., et al. Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey. BMJ Infect Dis 2013, 13:583.
26. Sancak B., Yagci S., Mirza H.C., Hascelik G. Evaluation of vancomycin and daptomycin MIC trends for methicillin-resistant Staphylococcus aureus blood isolates over an 11year. J Antimicrob Chemother 2013, 10.1093/jac/dkt247.
27. Stryjewski M.E., Corey G.R. Methicillin-resistant Staphylococcus aureus: an evolving pathogen. Clin Infect Dis 2014, 58(S1):S10-S19.
28. Tsukimori A., Nakamura I., Okanura S., Sato A., Fukushima S., Mizuno Y., et al. First case of vancomycin-intermediate sequence type 72 Staphylococcus aureus with non-susceptibility to daptomycin. BMC Infect Dis 2014, 14:459. [http://www.biomedcentral.com/147-2334/14/459].
29. van Hal S.J., Barbagiannakos T., Jones M., Wehrhahn M.C., Mercer J., Chen D., et al. Methicillin-resistant Staphylococcus aureus vancomycin susceptibility testing: methodology correlations, temporal trends and clonal patterns. J Antimicrob Chemother 2011, 66:2284-2487.
30. Zhang K., McClure J.-A., Elsayed S., Louie T., Conly J.M. Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette mec types I to V in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2005, 43:5026-5033.